Edition:
United Kingdom

Anthera Pharmaceuticals Inc (ANTH.OQ)

ANTH.OQ on NASDAQ Stock Exchange Capital Market

2.23USD
3:31pm GMT
Change (% chg)

$-0.13 (-5.51%)
Prev Close
$2.36
Open
$2.40
Day's High
$2.42
Day's Low
$2.17
Volume
197,358
Avg. Vol
152,438
52-wk High
$6.23
52-wk Low
$1.21

Chart for

About

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and... (more)

Overall

Beta: 2.64
Market Cap(Mil.): $18.00
Shares Outstanding(Mil.): 10.91
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 Sollpura Study

* ANTHERA ANNOUNCES POSITIVE OUTCOME OF SECOND INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA: STUDY ON SCHEDULE FOR TOPLINE DATA THIS QUARTER

22 Jan 2018

BRIEF-683 Capital Management Reports 6.1 Pct Passive Stake In Anthera Pharma

* 683 CAPITAL MANAGEMENT, LLC REPORTS A 6.1 PERCENT PASSIVE STAKE IN ANTHERA PHARMACEUTICALS INC AS OF JAN 8 - SEC FILING Source text: (http://bit.ly/2mOAqQ5)

18 Jan 2018

BRIEF-Anthera Pharma Appoints Patrick Murphy As Senior Vice President, Manufacturing

* ANTHERA PHARMACEUTICALS ANNOUNCES APPOINTMENT OF PATRICK MURPHY AS SENIOR VICE PRESIDENT, MANUFACTURING Source text for Eikon: Further company coverage:

03 Jan 2018

BRIEF-Anthera Pharmaceuticals Announces Positive Outcome In The Phase 3 Result Clinical Study Of Sollpura

* ANTHERA PHARMACEUTICALS ANNOUNCES POSITIVE OUTCOME OF INTERIM FUTILITY ANALYSIS IN THE PHASE 3 RESULT CLINICAL STUDY OF SOLLPURA

11 Dec 2017

BRIEF-Anthera Pharmaceuticals files for resale of up to 28.6 million shares of co's common stock

* Anthera Pharmaceuticals Inc files for resale of up to 28.6 million shares of co's common stock by the selling stockholders‍​ Source text: (http://bit.ly/2mmbjHr) Further company coverage:

13 Nov 2017

BRIEF-ANTHERA PHARMA REPORTS Q3 LOSS PER SHARE $0.58

* ANTHERA PHARMACEUTICALS PROVIDES BUSINESS UPDATE AND REPORTS 2017 THIRD QUARTER FINANCIAL RESULTS

06 Nov 2017

BRIEF-Armistice Capital reports 5.6 percent passive stake in Anthera Pharma

* Armistice Capital, Llc reports 5.6 percent passive stake in Anthera Pharmaceuticals Inc as on October 24, 2017 - SEC filing‍​ Source text: (http://bit.ly/2A4C2Kr) Further company coverage:

03 Nov 2017

BRIEF-Anthera Pharmaceuticals announces pricing of $15 mln private placement offering

* Anthera Pharmaceuticals announces pricing of $15 million private placement offering

24 Oct 2017

BRIEF-Anthera Pharma surpasses 50 pct milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

* Anthera Pharmaceuticals surpasses 50% milestone for screening of patients in result phase 3 clinical study of Sollpura in cystic fibrosis

07 Sep 2017

BRIEF-Anthera announces top line final data from extension period of phase 2 bright-SC study of blisibimod in patients with iGa nephropathy

* Anthera announces top line final data from the extension period of the phase 2 bright-sc study of blisibimod in patients with IgA nephropathy

28 Aug 2017

Earnings vs. Estimates